Intelligence Feed event · Equity · 2026-09-19

    Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity

    Question

    Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity

    Direct answer

    Teva Pharmaceutical released comparative real-world clinical data indicating that UZEDY (risperidone extended-release injectable suspension) achieved higher rates of treatment continuation compared to alternative long-acting injectable formulations in schizophrenia patients. The findings revealed reductions in acute emergency room admissions and total healthcare utilization costs. Furthermore, UZEDY outperformed oral antipsychotics in treatment persistence for bipolar I disorder patients, reinforcing Teva's commercial positioning in specialty CNS therapeutics.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-19
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity”, revision 1, evidence through 2026-09-19. https://marketontology.com/market-events/2026-09-19/teva-highlights-real-world-data-demonstrating-uzedy-superiority-in-treatment-con-e850d8

    EQUITY
    Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity
    Teva Pharmaceutical released comparative real-world clinical data indicating that UZEDY (risperidone extended-release injectable suspension) achieved higher rates of treatment continuation compared to alternative long-acting injectable formulations in schizophrenia patients. The findings revealed reductions in acute emergency room admissions and total healthcare utilization costs. Furthermore, UZEDY outperformed oral antipsychotics in treatment persistence for bipolar I disorder patients, reinforcing Teva's commercial positioning in specialty CNS therapeutics.
    TEVA
    Impact
    58
    SEP 19
    SIG
    85%
    TEVA
    Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity
    Teva Pharmaceutical released comparative real-world clinical data indicating that UZEDY (risperidone extended-release injectable suspension) achieved higher rates of treatment continuation compared to alternative long-acting injectable formulations in schizophrenia patients. The findings revealed reductions in acute emergency room admissions and total healthcare utilization costs. Furthermore, UZEDY outperformed oral antipsychotics in treatment persistence for bipolar I disorder patients, reinforcing Teva's commercial positioning in specialty CNS therapeutics.
    → Demonstrated reduction in hospitalizations and emergency visits accelerates UZEDY formulary placement and payer reimbursement adoption for Teva.
    Impact
    Teva Pharmaceutical released comparative real-world clinical data indicating that UZEDY (risperidone extended-release injectable suspension) achieved higher rates of treatment continuation compared to alternative long-acting injectable formulations in schizophrenia patients. The findings revealed reductions in acute emergency room admissions and total healthcare utilization costs. Furthermore, UZEDY outperformed oral antipsychotics in treatment persistence for bipolar I disorder patients, reinforcing Teva's commercial positioning in specialty CNS therapeutics.
    Affected
    TEVA
    Transmission
    Demonstrated reduction in hospitalizations and emergency visits accelerates UZEDY formulary placement and payer reimbursement adoption for Teva.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TEVACNS specialty revenue growth via commercial payer adoptionUp1-3mTeva published real-world data showing UZEDY reduced emergency care and healthcare costs in schizophrenia.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month